Kala Bio (KALA) Enterprise Value (2016 - 2026)
Kala Bio (KALA) posted Enterprise Value of -$8.8 million for Q1 2026, down 15.97% sequentially from -$7.6 million in Q4 2025, and up 79.24% YoY from -$4.9 million in Q1 2025.
Kala Bio (KALA) Enterprise Value (2016 - 2026) Analysis & Trends
Kala Bio has reported Enterprise Value for 11 years, with the latest figure at -$8.8 million in Q1 2026.
- Quarterly Enterprise Value rose 79.24% year-over-year to -$8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.8 million (up 79.24% YoY) and the FY2025 annual result came in at -$7.6 million, up 85.23% from the prior year.
- Enterprise Value declined to -$8.8 million in Q1 2026 per KALA's latest filing, from -$7.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$7.6 million in Q4 2025 and troughed at -$72.5 million in Q4 2022.
- A 5-year average of -$46.0 million and a median of -$50.9 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value sank 37.56% in 2023, then soared 85.23% in 2025.
- Over 5 years, Enterprise Value stood at -$72.5 million in 2022, then increased by 29.84% to -$50.9 million in 2023, then retreated by 0.56% to -$51.2 million in 2024, then jumped by 85.23% to -$7.6 million in 2025, then fell by 15.97% to -$8.8 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$8.8 million, -$7.6 million, and -$21.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | -8.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.76 Mn |
| Dec 31, 2025 | -7.56 Mn |
| Sep 30, 2025 | -21.10 Mn |
| Jun 30, 2025 | -31.94 Mn |
| Mar 31, 2025 | -42.22 Mn |
| Dec 31, 2024 | -51.18 Mn |
| Sep 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -54.20 Mn |
| Mar 31, 2024 | -48.48 Mn |
| Dec 31, 2023 | -50.90 Mn |
| Sep 30, 2023 | -56.06 Mn |
| Jun 30, 2023 | -59.18 Mn |
| Mar 31, 2023 | -63.64 Mn |
| Dec 31, 2022 | -72.54 Mn |
| Sep 30, 2022 | -52.39 Mn |
| Jun 30, 2022 | -43.02 Mn |
| Mar 31, 2022 | -70.16 Mn |
| Dec 31, 2021 | -94.18 Mn |
| Sep 30, 2021 | -124.50 Mn |
| Jun 30, 2021 | -149.64 Mn |